Atara Biotherapeutics, Inc.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $120.8M
- Net income
- $32.7M
- Total assets
- $20.2M
- Market cap
- $89.4M
- Operating margin
- 29.7%
- Net margin
- 27.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $120.8M
- Operating expenses
- $84.9M
- Operating income
- $35.9M
- Income tax
- $31.0K
- Net income
- $32.7M
- EPS (basic)
- $2.61
- EPS (diluted)
- $2.57
Balance sheet
- Total assets
- $20.2M
- Current assets
- $12.2M
- Total liabilities
- $58.7M
- Current liabilities
- $14.9M
- Shareholders’ equity
- -$38.5M
Cash flow
- Operating cash flow
- -$50.9M
- Investing cash flow
- $18.1M
- Financing cash flow
- $16.1M
- Net cash flow
- -$16.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $89.4M
- P/E ratio
- 3.7
- EPS (diluted)
- $2.57
- Shares outstanding
- 9.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 16, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $32.7M in FY2025.
- Revenue grew 494% from FY2021 to FY2025.
- Trading 47% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 3.7.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Atara Biotherapeutics, Inc..
Write a review
News about Atara Biotherapeutics, Inc.
News & sentiment via Polygon.io
